|
Strategic Partnerships
ApoImmune is developing several innovative platform technologies for immunotherapies and vaccines that can support various research and development projects. Currently, we are concentrating our clinical capabilities on cancer as we head toward our first Phase I clinical trial. Our other research programs include infectious disease, autoimmune disease with a focus on Type 1 diabetes, and cell/organ transplantation. To maximize the value of our proprietary technologies and products, ApoImmune seeks to collaborate or partner with research institutions and pharmaceutical and biotechnology companies.
For further information on strategic partnerships please contact one of the following:
Business Development Inquiries:
Steven Downey
President and CEO
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493, ext. 303
sdowney[at]apoimmune.com
Scientific Inquiries:
Dr. Rolf Huseby, Ph.D.
Vice President, Advanced Research and Product Development
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493, ext. 222
rhuseby[at]apoimmune.com
|
|
|
